Direkt zum Inhalt
Merck

E2-25K SUMOylation inhibits proteasome for cell death during cerebral ischemia/reperfusion.

Cell death & disease (2016-12-30)
Eun Il Jeong, Hae Won Chung, Won Jea Lee, Seo-Hyun Kim, Hyunjoo Kim, Seon-Guk Choi, Yong-Keun Jung
ZUSAMMENFASSUNG

Cerebral ischemia/reperfusion (I/R) causes brain damage accompanied by ubiquitin accumulation and impairment of proteasome activity. In this study, we report that E2-25K, an E2-conjugating enzyme, is SUMOylated during oxidative stress and regulates cerebral I/R-induced damage. Knockdown of E2-25K expression protects against oxygen/glucose deprivation and reoxygenation (OGD/R)-induced neuronal cell death, whereas ectopic expression of E2-25K stimulates it. Compared with the control mice, cerebral infarction lesions and behavioral/neurological disorders are ameliorated in E2-25K knockout mice during middle cerebral artery occlusion and reperfusion. In particular, E2-25K is SUMOylated at Lys14 under oxidative stress, OGD/R and I/R to prompt cell death. Further, E2-25K downregulates the proteasome subunit S5a to impair proteasome complex and thus restrain proteasome activity under oxidative stress. This proteasome inhibitory activity of E2-25K is dependent on its SUMOylation. These results suggest that E2-25K has a crucial role in oxidative stress and cerebral I/R-induced damage through inhibiting proteasome via its SUMOylation.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
MISSION® esiRNA, targeting human UBE2K